Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed versus pemetrexed + carboplatin in pretreated advanced NSCLC
NL-OMON26799Phase 2Active, not recruiting
- Sponsor
- NVALT
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NVALT. Primary endpoint: Time to progression. Started Sep 2005; status: active, not recruiting.
02
Drugs
pemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON26799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26799.